InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC
China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...
ADC / XDC
Alphamab Oncology Secures FDA Fast‑Track Designation for HER2 Bispecific ADC JSKN003 in Platinum‑Resistant Ovarian Cancer
China‑based Alphamab Oncology (HKG: 9966) announced today that the U.S. Food and Drug Administration (FDA)...
Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC
Alphamab Oncology (HKG: 9966), a China-based biotechnology company, announced on October 27, 2025, that its...
GSK Secures Global Rights to Syndivia’s ADC for Metastatic Prostate Cancer
British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that...
Alphamab Announces First Patient Dosed with JSKN022, a PD‑L1/αvβ6 Bispecific ADC
China‑based Alphamab Oncology (HKG: 9966) today announced that the first patient received a dose of...
Jiangsu Hengrui Secures NMPA Approval to Launch Phase III Trial of Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the National...
GSK Secures FDA Approval for Blenrep in Multiple Myeloma
GlaxoSmithKline (GSK, NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has...
PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...
Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies
Innovent Biologics, Inc. (HKG: 1801) today announced a landmark global strategic collaboration with Takeda Pharmaceutical...
Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...
AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...
Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient...
Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors
Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...
Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...
Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108
Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...
Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...
CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...
Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC
Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...
Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers
Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...
Kelun-Biotech’s Trastuzumab Botidotin Approved by NMPA for HER2-Positive Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on October 17, 2025, that its Human...